Advertisement

Pharmacy World and Science

, Volume 20, Issue 1, pp 1–17 | Cite as

The eradication treatments of Helicobacter pylori.

  • Joël Wermeille
  • Georges Zelger
  • Michael Cunningham
Article

Abstract

The eradication of Helicobacter pylori is at present widely recognized as the adequate therapeutic approach for gastric and duodenal ulcers in infected patients. In those with dyspepsia but no ulcer as well as in those with type B chronic gastritis, eradication remains controversial. It is difficult to have a clear opinion on the advantages and disadvantages of the numerous existing therapies. Therefore, a systematic review of published treatments has been made by the authors. Ideally, the eradication treatment of H. pylori should have the following advantages: 1. eradication superior to 90%. 2. simplicity. 3. short duration. 4. safety. 5. low cost. 6. reproducibility of results. Dual therapies (2 antibiotics or a proton pump inhibitor in combination with an antibiotic) rarely allow an eradication greater than 90% and the results have poor reproductibility. Consequently, they do not represent an ideal anti‐H. pylori treatment. Triple therapies come closer to the requirements for an ideal treatment, with eradication rates generally close to 90%, varying little between studies and the countries in which they were performed. The triple therapy bismuth‐imidazole‐tetracycline (or amoxicillin) still represents for many authors the standard reference therapy. It has the advantage of low cost, high efficacy and widespread use. It is the therapy that has been the most studied. However, the increasing emergence of strains resistant to imidazoles, the complexity of the treatment (10 to 12 tablets per day), the numerous adverse effects and the lack of availability of bismuth salts in certain countries has led to the elaboration of therapeutic schemes combining an antisecretory drug with 2 antibiotics. Among these, the combination PPI‐clarithromycine‐imidazole during 7 days represents the most studied triple therapy of short duration. For some authors, it already represents a new standard. However, the efficacy of this therapy seems dependent on the sensitivity of the bacteria to imidazoles. Consequently, this combination cannot be considered as the ideal anti‐H. pylori treatment in the areas where the prevalence of strains resistant to imidazoles is high. The association PPI‐clarithromycine‐amoxicillin appears on the contrary to be very effective against strains resistant to metronidazole and therefore could constitute the treatment of choice in population with high prevalence of such strains. Great hope is currently surrounding the finalization of a vaccine directed against the urease of the bacteria. This approach would allow both the treatment and the prevention of Helicobacter pylori infection on a large scale.

Helicobacter pylori Eradication Dual therapy Triple therapy Peptic ulcer Proton pump inhibitors H2‐receptor antagonists Antibiotics Bismuth 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; i:1273–5.Google Scholar
  2. 2.
    Graham DY. Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease. J Gastroenterol Hepatol 1991; 6:105–13.PubMedGoogle Scholar
  3. 3.
    Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;i:1311–5.Google Scholar
  4. 4.
    Marshall BJ. Helicobacter pylori: the etiologic agent for peptic ulcer. JAMA 1995;274:1064–6.PubMedGoogle Scholar
  5. 5.
    Megraud F. Epidemiology of Helicobacter pylori infection. In: Rathbone BJ and Heatley RV, eds. Helicobacter pylori and gastroduodenal disease. Oxford: Blackwell Scientific, 1992:107–123.Google Scholar
  6. 6.
    Peterson WL. Helicobacter pylori and peptic ulcer disease.N Engl J Med 1991;324:1043–8.PubMedGoogle Scholar
  7. 7.
    Noach LA, Tytgat GNJ. Clinical importance of Helicobacter pylori infection. In: Noach LA and Tytgat GNJ, eds. Helicobacter pylori infection. Aspects of pathogenesis and therapy. 2nd ed. Amsterdam: Datawyse Universitaire Pers Maastricht (ISBN 90 5278 105 2), 1994:11–26.Google Scholar
  8. 8.
    Malaty HM, Graham DY, Klein PD, Evans DG, Adams E, Evans DJ. Transmission of Helicobacter pylori infection. Studies in families of healthy individuals. Scand J Gastroenterol 1991;26:927–32.PubMedGoogle Scholar
  9. 9.
    Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ, Saeed ZA, Malaty HM. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. Ann Intern Med 1992;116:705–8.PubMedGoogle Scholar
  10. 10.
    Ruszniewski P, Lamouliatte H, Michot F, Fraleu-Louer B, Bretagne JF, Lacaine F. Quelle est la prise en charge thérapeutique de la maladie ulcéreuse duodénale en dehors de l'urgence? & Quelle est la prise en charge thérapeutique de la maladie ulcéreuse gastrique en dehors de l'urgence? Gastroentrol Clin Biol 1996;20:S53–S83.Google Scholar
  11. 11.
    Hentschel E, Brandstätter G, Dragosics B, Hirschl AM, Nemec H, Schütze K, Taufer M, Wurzer H. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993;328:308–12.CrossRefPubMedGoogle Scholar
  12. 12.
    Raab M, Said S, Hilgers RD, Pichlmayer H. Long-term results of highly selective vagotomy for the treatment of duodenal ulcer. Hepato-gastroenterol 1989;36:357–62.Google Scholar
  13. 13.
    Susi D, Neri M, Ballone E, Mezzetti A, Cuccurullo F. Five-year maintenance treatment with ranitidine: effects on the natural history of duodenal ulcer disease. Am J Gastroenterol 1994;89:26–32.PubMedGoogle Scholar
  14. 14.
    Obrien B, Goeree R, Mohamed AH, Hunt R. Cost-effectiveness of Helicobacter pylori eradication for long-term management of duodenal ulcer in Canada. Arch Intern Med 1995:155:1958–64.PubMedGoogle Scholar
  15. 15.
    Sonnenberg A, Townsend WF. Costs of duodenal ulcer therapy with antibiotics. Arch Intern Med 1995;155:922–28.CrossRefPubMedGoogle Scholar
  16. 16.
    Veldhuyzen van Zanten SJO, Sherman PM. Indications for treatment of Helicobacter pylori infection: a systematic overview. Can Med Assoc J 1994;150:189–98.Google Scholar
  17. 17.
    Graham DY, Lew GM, Evans DG, Evans DJ, Klein PD. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. Ann Intern Med 1991;115:266–9.PubMedGoogle Scholar
  18. 18.
    Labenz J, Börsch G. Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection. Am J Gastroenterol 1994;89:1785–8.PubMedGoogle Scholar
  19. 19.
    Rokkas T, Karameris A, Mavrogeorgis A, Rallis E, Giannikos N. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. Gastrointest Endosc 1995;41:1–4.PubMedGoogle Scholar
  20. 20.
    Jaspersen D, Koerner T, Schorr W, Brennenstuhl M, Raschka C, Hammar CH. Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage. Gastrointest Endosc 1995;41:5–7.PubMedGoogle Scholar
  21. 21.
    Jaspersen D, Koerner T, Schorr W, Brennenstuhl M, Raschka C, Hammar CH. Omeprazole-amoxicillin therapy for eradication of Helicobacter pylori in duodenal ulcer bleeding: preliminary results of a pilot study. J Gastroenterol 1995;30:319–21.PubMedGoogle Scholar
  22. 22.
    Graham DY, Hepps KS, Ramirez FC, Lew GM, Saeed ZA. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 1993;28:939–42.PubMedGoogle Scholar
  23. 23.
    NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65–9.Google Scholar
  24. 24.
    Société Nationale Française de Gastroentérologie, conférence de consensus. Maladie ulcéreuse et gastrites à l'heure d'Helicobacter pylori, conclusion et recommandations du Jury (texte de consensus). Gastroenterol Clin Biol 1996;20:S155–S162.Google Scholar
  25. 25.
    Hosking SW, Ling TKW, Chung SCS, Yung MY, Cheng AFB, Sung JJY, Li AKC. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomized controlled trial. Lancet 1994;343:508–10.PubMedGoogle Scholar
  26. 26.
    Sung JJY, Chung SCS, Ling TKW, Yung MY, Leung VKS, NG EKW, Li MKK, Cheng AFB, Li AKC. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995;332:139–42.CrossRefPubMedGoogle Scholar
  27. 27.
    Sung JJY, Chung SCS, Ling TKW, Suen R, Leung VKS, Lau JYW, Cheng AFB, Li AKC. Dual therapy versus triple therapy for Helicobacter pylori-associated duodenal ulcers. Dig Dis Sci 1996;41:453–7.PubMedGoogle Scholar
  28. 28.
    Labenz J, Adamek RJ, Peitz U, Tillenburg B, Wegener M, Idström JP, Rosen E, Börsch G. Duodenal ulcer healing: is one-week low-dose triple therapy sufficient (abstract)? Gastroenterology 1995;108:A140.Google Scholar
  29. 29.
    Labenz J, Tillenburg B, Stolte M, Adamek RJ, Becker T, Börsch G. Ulcer healing by eradicating Helicobacter pylori. Gastroenterology 1995;108:A140.Google Scholar
  30. 30.
    Tefera S, Berstad A, Bang CJ, Nysaeter G, Hatlebakk JG, Olafsson S, Nesje LB, Hausken T, Berstad, Hundal O. Bismuth-based combination therapy for Helicobacter pyloriassociated peptic ulcer disease (metronidazole for eradication, ranitidine for pain). Am J Gastroenterol 1996;91:935–41.PubMedGoogle Scholar
  31. 31.
    Reilly TG, Ayres RCS, Poxon V, Walt RP. Helicobacter pylori eradication in a clinical setting: success rates and the effect on the quality of life in peptic ulcer. Aliment Pharmacol Ther 1995;9:483–40.PubMedGoogle Scholar
  32. 32.
    Wilhelmsen I. Quality of life in upper gastrointestinal disorders. Scand J Gastroenterol 1995;30:21–5.Google Scholar
  33. 33.
    Tytgat GNJ. Current indications for Helicobacter pylori eradication therapy. Scand J Gastroenterol 1996;31 (Suppl 215):70–3.Google Scholar
  34. 34.
    Soll AH. Medical treatment of peptic ulcer disease. JAMA 1996;275:622–9.PubMedGoogle Scholar
  35. 35.
    Danquechin Dorval E, Picon L. Pourquoi éradiquer Helicobacter pylori? Gastroenterol Clin Biol 1994;18:229–31.PubMedGoogle Scholar
  36. 36.
    Bruley Des Varannes S, Scarpignato C. Infection à Helicobacter pylori: relations entre gastrite et symptomatologie clinique. Gastroenterol Clin Biol 1996;20:S84–S94.PubMedGoogle Scholar
  37. 37.
    Vouillamoz D, Schnegg JF, Duroux Ph, Schwizer W, Fraser R, Michetti P, Dorta G, Thorens J, Froehlich F, Fried M, Bretholz, Fasel J, Frei A, Guyot J, Margalith D, Gonvers JJ, Blum AL. Acquisitions thérapeutiques 1992: Affections peptiques. Méd & Hyg 1993;51:183–90.Google Scholar
  38. 38.
    Armstrong D. Helicobacter pylori infection and dyspepsia. Scand J Gastroenterol 1996;31 (Suppl 215):38–47.PubMedGoogle Scholar
  39. 39.
    Cunningham M. Unpublished observation 1996.Google Scholar
  40. 40.
    Sheu BS, Lin CY, Lin XZ, Shiesh SC, Yang HB, Chen CY. Long-term outcome of triple therapy in Helicobacter pylori-related nonulcer dyspepsia: a prospective controlled assessment. Am J Gastroenterol 1996;91:441–7.PubMedGoogle Scholar
  41. 41.
    Recavarren Arce S, Leon Barua R, Cok J, Berendson R, Gilman RH, Ramirez-Ramos A Rodriguez C, Spira WM. Helicobacter pylori and progressive gastric pathology that predisposes to gastric cancer. Scand J Gastroenterol 1991;26 (Suppl 181):51–57.Google Scholar
  42. 42.
    Correa P. A human model of gastric carcinogenesis. Cancer Res 1988;48:3554–560.PubMedGoogle Scholar
  43. 43.
    Buckley M, O'Morain C. Quand faut-il éradiquer Helicobacter pylori? Gastroenterol Clin Biol 1996;20:S95–S102.PubMedGoogle Scholar
  44. 44.
    Bouché O. Faut-il éradiquer Helicobacter pylori chez un malade ayant une gastrite chronique? Gastroenterol Clin Biol 1996;20:S143–S153.PubMedGoogle Scholar
  45. 45.
    Dixon MF. Campyloobacter pylori and chronic gastritis. In: Rathbone BJ and Heatley RV, eds. Helicobacter pylori and gastroduodenal disease. Oxford: Blackwell Scientific, 1989:106–16.Google Scholar
  46. 46.
    Morris A, Nicholson G. Campyloobacter pylori: human ingestion studies. In: Rathbone BJ and Heatley RV, eds. Helico-bacter pylori and gastroduodenal disease. Oxford: Blackwell Scientific, 1989:185–9.Google Scholar
  47. 47.
    Mainguet P, Jouret A, Haot J. Le "sydney System', nouvelle classification des gastrites. Gastroenterol Clin Biol 1993;17:T13–T17.PubMedGoogle Scholar
  48. 48.
    Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogel JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127–31.PubMedGoogle Scholar
  49. 49.
    International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC monographs on the evaluation of carcinogenic risk to humans. Lyon: IARC 1994;61:177–241.Google Scholar
  50. 50.
    Bayerdörffer E, Neubauer A, Burkhard R, Thiede C, Lehn N, Eidt S, Stolte M. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet 1995;345:1591–4.CrossRefPubMedGoogle Scholar
  51. 51.
    Cammarota G, Montalto M, Tursi A, Papa A, Cuoco L, Certo M, Armuzzi A, Addolorato G, Fedeli G, Gasbarrini G. Disappearance of gastric acquired MALT and regression of low-grade B-cell gastric lymphoma by mean anti-H. pylori treatment. Gastroenterology 1995;108 (Suppl) A65.Google Scholar
  52. 52.
    Savio A, Franzin G, Wotherspoon AC, Zamboni G, Negrini R, Graffeo M, Diss TC, Pan L, Isaacson PG. Long-term effect of anti-Helicobacter pylori therapy on gastric MALT lymphoma. Histological and molecular evaluation of 15 cases. Gut 1995;37 (Suppl):A6Google Scholar
  53. 53.
    Bayerdörffer E, Ritter MM, Hatz R, Brooks W, Ruckdeschel G, Stolte M. Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter pylori-is Helicobacter pylori a pathogenic factor in Ménétrier's disease. Gut 1994;35:701–4.PubMedGoogle Scholar
  54. 54.
    Murray DM. Clinical relevance of infection by Helicobacter pylori. Clin Microbiol Newsl 1993;15:33–7.CrossRefGoogle Scholar
  55. 55.
    Goodwin CS, McNulty CAM. Bacteriological and pharmacological basis for the treatment of Helicobacter pylori infection. In: Rathbone BJ and Heatley RV, eds. Helicobacter pylori and gastroduodenal disease. Oxford: Blackwell Scientific 1992:224–31.Google Scholar
  56. 56.
    Anderson LP. Cytoprotective agents and C. pylori associated acid peptic diseases. Scand J Gastroenterol 1988;23 (Suppl 142) 110–3.Google Scholar
  57. 57.
    Noach LA, Bertola MA, Schwartz MP, Rauws EAJ, Tytgat GNJ. Treatment of Helicobacter pylori infection. An evaluation of various therapeutic trials and review of the literature. In: Noach LA and Tytgat GNJ, eds. Helicobacter pylori infection. Aspects of pathogenesis and therapy. 2nd ed. Amsterdam: Datawyse Universitaire Pers Maastricht (ISBN 90 5278 105 2), 1994:83–125. Published in part in Eur J Gastroenterol Hepatol 1994;6:585-91.Google Scholar
  58. 58.
    Lamouliatte H. Effect of Lansoprazole on Helicobacter pylori. Clin Ther 1993;15 (Suppl B):32–6.PubMedGoogle Scholar
  59. 59.
    Chiba N, Rao BV, Rademaker JW, Hunt RH. Meta-analysis of efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992;87:1716–27.PubMedGoogle Scholar
  60. 60.
    Bader JP. The safety profile of De-Nol®. Digestion 1987;37 (Suppl 2):53–9.PubMedGoogle Scholar
  61. 61.
    Marshall BJ, Armstrong JA, Francis GJ, Nokes NT, Wee SH. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion 1987;37 (suppl 2):16–30.PubMedGoogle Scholar
  62. 62.
    Lee FI, Samloff IM, Hardman M. Comparison of tripotassium dicitrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. Lancet 1985;i:1299–302.CrossRefGoogle Scholar
  63. 63.
    Tytgat GNJ. Colloidal bismuth subcitrate in peptic ulcer-a review. Digestion 1987;37 (suppl 2):31–41.PubMedGoogle Scholar
  64. 64.
    Adamek RJ, Wegener M, Labenz J, Freitag M, Opferkuch W, Rühl GH. Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy. Am J Gastroenterol 1994;89:39–42.PubMedGoogle Scholar
  65. 65.
    Rokkas T, Mavrogeorgis A, Liatsos C, Rallis E, Kalogeropoulos N. Optimal dose of omeprazole in combination with amoxicillin in eradicating Helicobacter pylori and preventing relapses in duodenal ulcer patients. Hepato-gastroenterol 1995;42:842–46.Google Scholar
  66. 66.
    Midolo PD, Korman MG, Turnidge JD, Lambert JR. Helicobacter pylori resistance to tetracycline (letter). Lancet 1996;347:1194–95.CrossRefGoogle Scholar
  67. 67.
    Veldhuyzen Van Zanten SJO, Goldie J, Hollingsworth J, Silletti C, Richardson H, Hunt RH. Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori. J Clin Pathol 1992;45:225–27.PubMedGoogle Scholar
  68. 68.
    Noach LA, Langenberg WL, Bertola MA, Dankert J, Tytgat GNJ. Impact of metronidazole resistance on the eradication of Helicobacter pylori. Scand J Infect Dis 1994;26:321–27.PubMedGoogle Scholar
  69. 69.
    Sieber CC, Frei R, Beglinger C, Mossi S, Binek J, Schaufelberger H, Fried R, Stalder GA. Helicobacter pylori resistance against metronidazole in Switzerland: implication for eradication therapy? Schweiz Med Wochenschr 1994;124:1381–4.PubMedGoogle Scholar
  70. 70.
    Marchi M, Vacondio R, Bagnulo A, Mengoli M. Azithromycin-omeprazole. Treatment for the eradication of Helicobacter pylori. Minerva Gastroenterol Dietol 1994;40:47–9.PubMedGoogle Scholar
  71. 71.
    Al-Assi MT, Genta RM, Karttunen TJ, Cole RA, Graham DY. Azithromycin triple therapy for Helicobacter pylori infection: azithromycin, tetracycline, and bismuth. Am J Gastroenterol 1995;90:403–5.PubMedGoogle Scholar
  72. 72.
    Dammann HG, Bilke R, Burkhardt F, Wolf N, Walter TA. Roxithromycine in triple therapy for H. pylori eradication (abstract). Gastroenterology 1996;110:A90.Google Scholar
  73. 73.
    Lamouliatte H, Courrier A, Mion F, Mégraud F, Rio Y, Reverdy ME, Fléjou JF, Topeza M. Triple therapy with roxithromycinamoxicillin and lansoprazole for Helicobacter pylori eradication: results of an open multicentre study (abstract). Gastroenterology 1996;110:A171.Google Scholar
  74. 74.
    Bertoni G, Sassatelli R, Nigrisoli E, Tansini P, Bianchi G, Della Casa G, Bagni A, Bedogni G. Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. Am J Gastroenterol 1996;91:258–63.PubMedGoogle Scholar
  75. 75.
    Di Mario F, Dal Bo N, Grassi SA, Rugge M, Cassaro M, Donisi PM, Vianello F, Kusstatscher S, Salandin S, Grasso GA, Ferrana M, Battaglia G. Azithromycin for the cure of Helicobacter pylori infection. Am J Gastroenterol 1996;91:264–7.PubMedGoogle Scholar
  76. 76.
    Hardy DJ, Hanson CW, Hensey DM, Beyer JM, Fernandes PB. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. J Antimicrob Chemother 1988;22:631–6.PubMedGoogle Scholar
  77. 77.
    Peitz U, Nusch A, Tillenburg B, Becker T, Stolte M, Börsch G, Labenz J. Frequent metronidazole resistance without significant impact on the high cure rate of Helicobacter pylori infection by triple therapy with omeprazole, metronidazole, and clarithromycin (abstract). Gastroenterology 1996;110:A226.Google Scholar
  78. 78.
    Murakami K, Fujioka T, Kubota T, Kodama R, Tokieda M, Nasu M. Evidence of Helicobacter pylori resistance to antibiotics in non-eradicated cases treated with new triple therapy (abstract). Gastroenterology 1996;110:A203.Google Scholar
  79. 79.
    Cayla R, Zerbib F, Talbi P, Mégraud F, Lamouliatte H. Pre and post-treatment clarithromycin resistance of Helicobacter pylori strains: a key factor of treatment failure (abstract). Gut 1995;37 (Suppl 1):A55.Google Scholar
  80. 80.
    Xia HX, Buckley M, Hyde D, Keane CT, O'Morain CA. Effect of antibiotic-resistance on clarithromycin-combined triple therapy for Helicobacter pylori (abstract). Gut 1995;37 (Suppl 1):A55.Google Scholar
  81. 81.
    Pryce DI, Harris AW, Gabe SM, Karim QN, Beveridge I, Langworthy H, Walker MM, Misiewicz JJ, Baron JH. One week of lansoprazole, clarithromycin and metronidazole eradicates Helicobacter pylori (abstract). Gastroenterology 1996;110:A235.Google Scholar
  82. 82.
    Xia HX, Buckley M, Keane CT, O'Morain CA. Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro. J Antimicrob Chemother 1996;37:473–81.PubMedGoogle Scholar
  83. 83.
    De Koster E, Cozzoli A, Jonas C, Ntounda R, Butzler JP, Deltenre M. Resistance of Helicobacter pylori to macrolides and imidazoles: a six years surveillance study. Gastroenterology 1996;110:A93.Google Scholar
  84. 84.
    Glupczynski Y, Goutier S, Van den Borre C, Butzler JP, Burette A. Surveillance of Helicobacter pylori resistance to antimicrobial agents in Belgium from 1989 to 1994 (abstract). Gut 1995;37 (ppl 1):A56.Google Scholar
  85. 85.
    Cayla R, Lamouliatte H, Brugmann M, Megraud F. Pre-treatment resistances of Helicobacter pylori to metronidazole and macrolides (abstract). Acta Gastroenterol Belg 1993;56 (Suppl):A65.Google Scholar
  86. 86.
    Berstad A, Alexander B, Weberg R, Serck-Hanssen A, Holland S, Hirschowitz BI. Antacids reduce Campylobacter pylori colonisation without healing the gastritis in patients with non-ulcer dyspepsia and erosive prepyloric changes. Gastroenterology 1988;95:619–24.PubMedGoogle Scholar
  87. 87.
    Hirschel AM, Hentschl E, Schütze K Nemec H, Pötzi R, Gangl A, Weiss W, Pletschette M, Stanek G, Rotter ML. The efficacy of antimicrobial treatment in Campylobacter pylori-associated gastritis and duodenal ulcer. Scand J Gastroenterol 1988;23 (Suppl 142):76–81.Google Scholar
  88. 88.
    Holtermuller KH, Liszkay M, Bernard I, Haase W. Therapy of stomach ulcer · a comparison between the low dosage antacid hydrotalcite and ranitidine · results of a randomized multicenter double-blind study. Z Gastroenterol 1992;30:717–21.PubMedGoogle Scholar
  89. 89.
    Lamouliatte H. Traitement des gastrites chroniques associées à Campylobacter pylori. Gastroenterol Clin Biol 1989;13:B101–B106.Google Scholar
  90. 90.
    Banerjee S, El-omar E, Mowat A, Ardill JES, Park RHR, Watson W, Beattie AD, McColl KEL. Sucralfate suppresses Helicobacter pylori infection and reduces gastric acid secretion by 50% in patients with duodenal ulcer. Gastroenterology 1996;110:717–24.PubMedGoogle Scholar
  91. 91.
    Slomiany BL, Piotrowski J, Majka J, Slomiany A. Sucralfate affects the susceptibility of Helicobacter pylori to antimicrobial agents. Scand J Gastroenterol 1995;30 (Suppl 210):82–84.Google Scholar
  92. 92.
    Lam SK, Hu WHC, Ching CK. Sucralfate in Helicobater pylori eradication strategies. Scand J Gastroenterol 1995;30 (Suppl 210):89–91.Google Scholar
  93. 93.
    Labenz J, Gyenes E, Ruhl GH, Börsch G. Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study. Gut 1993;34:1167–70.PubMedGoogle Scholar
  94. 94.
    Frotz H, Ahrends H, Hebbeln H, Klass D, Miederer SE, Mittelstaedt A, Rolfs HC, Von Geldern R. Ranitidine and clarithromycin eradication of Helicobacter pylori in patients with duodenal ulcer. Arzneimittelforschung 1995;45:184–6.PubMedGoogle Scholar
  95. 95.
    Dettmer A. Ranitidine and amoxicillin for eradication of Helicobacter pylori in patients with duodenal ulcer. Arzneimittelforschung 1995;45:604–7.PubMedGoogle Scholar
  96. 96.
    Rauws EAJ, Tytgat GNJ. Helicobacter pylori: treatment of gastritis. In: Rathbone BJ and Heatley RV, eds. Helicobacter pylori and gastroduodenal disease. Oxford: Blackwell Scientific, 1992:232–43.Google Scholar
  97. 97.
    Adamek RJ, Wegener M, Birkholz S, Opferkuch W, Ruhl GH, Ricken D. Modified combined omeprazole/amoxicillin therapy for Helicobacter pylori eradication: a pilot study. Leber Magen Darm 1992:22:222–4.PubMedGoogle Scholar
  98. 98.
    Labenz J, Gyenes E, Ruhl GH, Börsch G. Two weeks treatment with amoxicillin/omeprazole for eradication of Helicobacter pylori. Z Gastroenterol 1992;30:776–8.PubMedGoogle Scholar
  99. 99.
    Logan RPH, Rubio MA, Gummett PA, Hegarty B, Walker MM, Baron JH. Omeprazole and amoxycillin suspension for Helicobacter pylori (abstract). Ir J Med Sci 1992;161 (Suppl 10):16.PubMedGoogle Scholar
  100. 100.
    Wagner S, Bleck J, Gebel M, Bär W, Mannes M. What treatment is best for gastric Helicobacter pylori infection (abstract)? Ir J Med Sci 1992;161 (Suppl 10):16.PubMedGoogle Scholar
  101. 101.
    Rokkas T, Mavrogeorgis A, Liatsos C, Rallis E. Optimal dose of omeprazole in combination with amoxicillin in eradicating Helicobacter pylori and preventing relapses in duodenal ulcer patients. Hepato-gastroenterol 1996;42:842–6.Google Scholar
  102. 102.
    Atherton JC, Hudson N, Kirk GE, Hawkey CK, Spiller RC. Amoxicillin capsules with omeprazole for the eradication of Helicobacter pylori. Assessment of the importance of antibiotic dose timing in relation to meals. Aliment Pharmacol Ther 1994;8:495–8.PubMedGoogle Scholar
  103. 103.
    Goh KL, Peh SC, Parasakthi N, Wong NW, Tan KK, Lo YL. Omeprazole 40mg o.m. combined with amoxycillin alone or with amoxicillin and metronidazole in the eradication of Helicobacter pylori. Am J Gastroenterol 1994;89:1789–92.PubMedGoogle Scholar
  104. 104.
    Labenz J, Ruhl GH, Bertrams J, Börsch G. Effective treatment after failure of omeprazole plus amoxicillin to eradicate Helicobacter pylori infection in peptic ulcer disease. Aliment Pharmacol Ther 1994;8:323–7.PubMedGoogle Scholar
  105. 105.
    Labenz J, Ruhl GH, Bertrams J, Börsch G. Medium-or high-dose omeprazole plus amoxicillin eradicates Helicobacter pylori in gastric ulcer disease. Am J Gastroenterol 1994;89:726–30.PubMedGoogle Scholar
  106. 106.
    Labenz J, Ruhl GH, Bertrams J, Börsch G. Medium-or high-dose omeprazole plus amoxicillin for eradication of Helicobacter pylori in duodenal ulcer disease. Dig Dis Sci 1994;39:1483–7.PubMedGoogle Scholar
  107. 107.
    Logan RPH, Schaufelberger HD, Gummett PA, Baron JH, Misiewicz JJ. Eradication of Helicobacter pylori with dual therapy. Second International Conference on the Macrolides, Azalides and Streptogramins 1994;Venice (Italy).Google Scholar
  108. 108.
    Tyszkiewicz T, Gerlee M, Wadström T. Lanzoprazole/amoxycillin versus omeprazole/amoxycillin in Helicobacter pylori eradication. (abstract). Helicobacter pylori Symposium 1994;Houston (Texas).Google Scholar
  109. 109.
    Al-Assi MT, Cole RA, Karttunen TJ, El-Zimaity H, Genta RM, Graham DY. Treatment of Helicobacter pylori infection with omeprazole-amoxicillin combination therapy versus ranitidine/sodium bicarbonate-amoxicillin. Am J Gastroenterol 1995;90:1411–4.PubMedGoogle Scholar
  110. 110.
    Cayla R, De Mascarel A, Zerbib F, Mégraud F, Jouret-Collin M, Forestier S, Lamouliatte H. High dose of lansoprazole plus amoxicillin versus high dose of lansoprazole plus amoxicillin and clarithromycin for Helicobacter pylori (abstract). Gastroenterology 1995;108:A68.Google Scholar
  111. 111.
    Graham KS, Malaty H, El-Zimaity HM, Genta RM, Cole RA, Al-Assi MT, Yousfi MM, Neil GA, Graham DY. Variability with omeprazole-amoxicillin combinations for treatment of Helicobacter pylori infection. Am J Gastroenterol 1995;90:1415–8.PubMedGoogle Scholar
  112. 112.
    Laine L, Stein C, Neil G. Limited efficacy of omeprazolebased dual and triple therapy for Helicobacter pylori: a randomized trial employing ‘optimal’ dosing. Am J Gastroenterol 1995;90:1407–10.PubMedGoogle Scholar
  113. 113.
    Parente F, Maconi G, Bargiggia S, Colombo E, Moayeddi P, Bianchi Porro G. Efficacy of amoxycillin compared with classical triple therapy in the eradication of H. pylori after pretreatment with lansoprazole (abstract). Gut 1995;37 (Suppl 1):A41.Google Scholar
  114. 114.
    Saberi-Firoozi M, Massarrat S, Zare S, Fattahi M, Javan A, Etaati H, Dehbashi N. Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year followup period: a prospective, randomized, controlled study. Am J Gastroenterol 1995:90:1419–23.PubMedGoogle Scholar
  115. 115.
    Soulé JC, Courrier A, Bigard MA, Roux D, Mion F, Lamouliatte H, Flejou JF, Mégraud F. Efficacy of Lansoprazole plus one or two antibiotics for Helicobacter pylori eradication (abstract). Gastroenterology 1995;108:A224.Google Scholar
  116. 116.
    Meining A, Höchter W, Weingart J, Simon Th, Krämer W, Klann H, Bolle KH, Sommer A, Lehn N, Stolte M, Bayerdörffer E. Omeprzole + clarithromycin + metronidazole versus omeprazole + amoxicillin for cure of Helicobacter pylori infection in duodenal ulcer patients (abstract). Gastroenterology 1996;110:A193.Google Scholar
  117. 117.
    Vanderhulst RWM, Weel JFL, Verheul SB, Keller JJ, Tenkate FJW, Vandenende A, Rauws EAJ, Dankert J, Tytgat GNJ. Treatment of Helicobacter pylori infection with low or high dose omeprazole combined with amoxycillin and the effect of early retreatment. Aliment Pharmacol Ther 1996;10:165–171.PubMedGoogle Scholar
  118. 118.
    Burette A, Glupczynski Y, De Prez C, De Koster E, Urbain D, Vanderauwera J, Wigerinck A, Drnec J. Omeprazole alone or in combination with clarithromycin for eradication of H. pylori: results of a randomized double-blind controlled study (abstract). Gastroenterology 1993;104:A49.Google Scholar
  119. 119.
    Neri M, Susi D, Seccia G, Di Iorio P, Laterza F, Cuccurullo F. Bismuth is a necessary addition to omeprazole and clarythromycin for the treatment of Helicobacter pylori-related gastritis (abstract). Gastroenterology 1993;104:A157.Google Scholar
  120. 120.
    Greaves RG, Cayla R, Mendelson MG, Lamouliatte H, Gummet PA, Baron JH, Megraud F, Logan RH, Misiewicz JJ. Omeprazole versus clarithromycin and omeprazole for eradication of H. pylori infection (abstract). Gastroenterology 1994;106:A84.Google Scholar
  121. 121.
    Gurbuz AK, Giardiello FM, Dagalp K, Karaeren N, Alper A, Pasricha PJ. Clarithromycin and omeprazole for Helicobacter pylori gastritis: an unsatisfactory regimen (abstract). Gastroenterology 1994;106:A85.Google Scholar
  122. 122.
    Logan RP, Gummett PA, Schaufelberger HD, Greaves RR, Mendelson GM, Walker MM, Thomas PH, Baron JH, Misiewicz. Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 1994;35:323–6.PubMedGoogle Scholar
  123. 123.
    Neri M, Susi D, Di Iorio P, Seccia G, Laterza F, Cuccurullo F. High-dose omeprazole with clarithromycin for one week: an effective dual therapy regimen for H. pylori infection (abstract). Gastroenterology 1994;106:A148.Google Scholar
  124. 124.
    Harris AW, Gummett PA, Logan RPH, Ashworth HM, Baron JH, Misiewicz JJ. Eradication of Helicobacter pylori with lansoprazole and clarithromycin. Aliment Pharmacol Ther 1995;9:201–4.PubMedGoogle Scholar
  125. 125.
    Hunt R, Schwartz H, Fitch D, Fedorak R, Al Kawas F, Vakil N. Dual Therapy of clarithromycin and omeprazole for treatment of patients with duodenal ulcers associated with Helicobacter pylori infection (abstract). Gut 1995;37 (Suppl 1):A5.Google Scholar
  126. 126.
    Katelaris PH, Patchett SE, Zhang ZW, Domizio P, Farthing MJG. A randomized prospective comparison of clarithromycin versus amoxycillin in combination with omeprazole for eradication of Helicobacter pylori. Aliment Pharmacol Ther 1995;9:205–8.PubMedGoogle Scholar
  127. 127.
    Logan RPH, Bardhan KD, Celestin LR, Theodossi A, Palmer KR, Reed PI, Baron JH, Misiewicz JJ. Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin. Aliment Pharmacol Ther 1995;9:417–3.PubMedGoogle Scholar
  128. 128.
    O'Morain C, Logan RPH. Clarithromycin in combination with omeprazole for healing of duodenal ulcers (DU), prevention of DU recurrence, and eradication of H. pylori in two European studies (abstract). Gut 1995;37 (Suppl):A4.Google Scholar
  129. 129.
    Takimoto T, Ido K, Taniguchi Y, Satoh K, Saifuku K, Kihira K, Yoshida Y, Kimura K. Efficacy of lansoprazole in eradication of Helicobacter pylori. J Clin Gastroenterol 1995;20 (Suppl 2P):S121–24.PubMedGoogle Scholar
  130. 130.
    Labenz J, Gyenes E, Ruhl GH, Börsch G. Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori. Am J Gastroenterol 1993;88:491–95.PubMedGoogle Scholar
  131. 131.
    Cayla R. Comment éradiquer Helicobacter pylori? Gastroentrol Clin Biol 1996;20:S119–S130.Google Scholar
  132. 132.
    Labenz J. Traitement de l'infection à Helicobacter pylori sous omeprazole et clarithromycine: situation actuelle. Leber Magen Darm 1994;24:203–9.PubMedGoogle Scholar
  133. 133.
    Borody T, Cole P, Noonan S, Morgan A, Ossip G, Maysey J Brandl S. Long-term Campylobacter pylori recurrence posteradication (abstract). Gastroenterology 1988;94:A43.Google Scholar
  134. 134.
    Rodionoff P, Hyland L, Ostapowicz N, Morgan A, Cole P, George L, Brandl S, Andrews P, Borody T. Triple therapy for Helicobacter pylori eradication-1,2 or 4 week (abstract)? The World Congresses of Gastroenterology 1990;Sydney (Australia):PP938.Google Scholar
  135. 135.
    Bell GD, Powell K, Burridge SM, Pallecaros A, Jones PH, Gant PW, Harrison G, Trowell JE. Experience with ‘triple’ anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resisitance. Aliment Pharmacol Ther 1992;6:427–435PubMedGoogle Scholar
  136. 136.
    Daskalopoulos G, Carrick J, Lian R, Lee A. Optimising therapy for H. pylori gastritis (abstract). Ir J Med Sci 1992;161 (Suppl 10):16.PubMedGoogle Scholar
  137. 137.
    Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ, Klein PD, Alpert LC, Genta RM. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992;102:493–96.PubMedGoogle Scholar
  138. 138.
    Labenz J, Gyenes E, Rühl GH, Börsch G. Efficiency of oral triple therapy (BSS/metronidazole/tetracycline) to eradicate Helicobacter pylori in duodenal ulcer disease (abstract). Ir J Med Sci 1992;161 (Suppl 10):90.Google Scholar
  139. 139.
    Sobala GM, George R, Tomkins D, Finlay J, Manning A. Spontaneous healing of duodenal ulcers after eradication of Helicobacter pylori (abstract). Ir J Med Sci 1992;161 (Suppl 10):5.PubMedGoogle Scholar
  140. 140.
    Balatsos V, Delis V, Skandalis N, Archimandritis A. Triple therapy after duodenal ulcer healing with omeprazole or ranitidine eradicates H. pylori and prevents ulcer relapses: preliminary results of a year follow up study. Gastroenterology 1993;104:A37.Google Scholar
  141. 141.
    Cutler AF, Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterology 1993;88:505–9.Google Scholar
  142. 142.
    Thijs JC, Van Zwet AA, Oey HB. Efficacy and side effects of a triple drug regimen for the eradication of Helicobacter pylori. Scand J Gastroenterol 1993;28:934–8.PubMedGoogle Scholar
  143. 143.
    Iser JH, Buttigieg RJ, Iseli A. Low dose, short duration therapy for the eradication of Helicobacter pylori in patients with duodenal ulcer. Med J Aust 1994;160:192–6.PubMedGoogle Scholar
  144. 144.
    De Boer W, Driessen W, Jansz A, Tytgat G. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 1995;345:817–20.CrossRefPubMedGoogle Scholar
  145. 145.
    Phull PS, Griffiths AE, Halliday D, Jacyna MR. One week treatment for Helicobacter pylori infection: a randomised study of quadruple therapy versus triple therapy. J Antimicrob Chemother 1995;36:1085–88.PubMedGoogle Scholar
  146. 146.
    Börsch G, Mai U, Opferkuch W. Short-and medium-term results of oral triple therapy to eradicate C. pylori (abstract). Gastroenterologiy 1989;96:A53.Google Scholar
  147. 147.
    Rautelin H, Seppala K, Renkonen OV, Vainio U, Kosunen TU. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother 1992;36:163–66.PubMedGoogle Scholar
  148. 148.
    Seppala K, Farkkila M, Nuutinen H, Hakala K, Vaananen H, Rautelin H, Kosunen TU. Triple therapy of Helicobacter pylori infection in peptic ulcer. Scand J Gastroenterol 1992;27:973–76.PubMedGoogle Scholar
  149. 149.
    Tucci A, Poli L, Gasperoni S, Varoli O, Paparo GF, De Giorgio R, Stanghellini V, Corinaldesi R. Evaluation of two therapeutic regimens for the treatment of Helicobacter pylori infection. Ital J Gastroenterol 1994;26:107–110.PubMedGoogle Scholar
  150. 150.
    Chen TS, Tsay SH, Chang FY, Lee SD. Triple therapy for the eradication of Helicobacter pylori and reduction of duodenal ulcer relapse: comparison of 1 week and 2 week regimens and recrudescence rates over 12 months. J Gastroenterol Hepatol 1995;10:300–5.PubMedGoogle Scholar
  151. 151.
    Lambert JR, Lin SK, Schembri M, Nicholson L, Korman MG. Helicobacter pylori therapy randomized study of denol/antibiotic combinations (abstract). Rev Esp Enferm Dig 1990;78 (Suppl 1):115–16.PubMedGoogle Scholar
  152. 152.
    Rauws EAJ, Noach LA, Heebels AE. Short-term regimens to eradicate Helicobacter pylori (abstract). The World Congresses of Gastroenterology 1990;Sydney (Australia): PP566.Google Scholar
  153. 153.
    Lambert JR, Midolo PD, Turnidge J. Metronidazole resistance-an important predictor of failur to eradicate Helicobacter pylori by triple therapy (abstract). Gastroenterology 1994;106 (Suppl):A120.Google Scholar
  154. 154.
    De Boer WA, Tytgat GN. The best therapy for Helicobacter pylori infection: should efficacy or side-efect profile determine our choice?. Scand J Gastroenterol 1995;30:401–7.PubMedGoogle Scholar
  155. 155.
    De Boer WA, Driessen WM, Potters VP, Tytgat GN. Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori. Am J Gastroenterol 1994;89:1993–97.PubMedGoogle Scholar
  156. 156.
    Kihira K, Kimura K, Satoh K, Takimoto T, Saifuku K, Taniguchi Y, Kojima T, Tokumaru K, Yamamoto H. Effect of 1-week triple therapy for Helicobacter pylori infection with lansoprazole or ranitidine and clarithromycin and metronidazole (abstract). Gastroenterology 1996;110:A154.Google Scholar
  157. 157.
    Spadaccini A, De Fanis C, Sciampa G, Pantaleone U, Di Virgilio M, Magnarini C, Pizzicannella G. Ranitidine vs omeprazole: short-term triple therapy in patients with Helicobacter pylori positive duodenal ulcer (abstract). Gut 1995;37 (Suppl 1):A42.Google Scholar
  158. 158.
    Yousfi MM, Elzimaity HM, Cole RA, Genta RM, Graham DY. Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1996;10:119–122.CrossRefGoogle Scholar
  159. 159.
    Al-Assi MT, Genta RM, Karttunen TJ, Graham DY. Clarithromycin-amoxycillin therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1994;8:453–6.PubMedGoogle Scholar
  160. 160.
    Lamouliatte H, Bernard Ph, Cayla R, Mégraud F, De Mascarel A, Quinton A. Controlled study of omeprazole-amoxicillintinidazole versus ranitidine-amoxicillin-tinidazole in Helicobacter pylori associated duodenal ulcers. Final and long-term results (abstract). Gastroenterology 1992;102 (Suppl):A106.Google Scholar
  161. 161.
    Powell KU, Bell GD, Bowden A, Harrison G, Trowell JE, Gant P, Jones PH. Helicobacter pylori eradication therapy: a comparison between either omeprazole or ranitidine in combination with amoxycillin plus metronidazole (abstract). Gut 1994;35 (Suppl 5):S15.PubMedGoogle Scholar
  162. 162.
    Lahaie RG, Lemoyne M, Poitras P, Gagnon M, Martin F, Boivin, Plourde V. A randomized trial of the efficacy of three regimens for the eradication of Helicobacter pylori (abstract). Gastroenterology 1995;108:A141.Google Scholar
  163. 163.
    Bazzoli F, Zagari RM, Fossi S, Pozzato P, Roda A, Roda E. Efficacy and tolerability of a short term, low dose triple therapy for eradication of Helicobacter pylori (abstract). Gastroenterology 1993;104:A40.Google Scholar
  164. 164.
    Bazzoli F, Zagari RM, Fossi S, Pozzato P, Alampi G, Simoni P. Short term, low dose triple therapy for eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994;6:773–77.Google Scholar
  165. 165.
    Moayyedi P, Axon ATR. Efficacy of a new one week triple therapy regime in eradicating Helicobacter pylori (abstract). Gut 1994;35 (Suppl 2):S62.Google Scholar
  166. 166.
    Moayyedi P, Tompkins DS, Axon ATR. Determination of the optimum dose of omeprazole in a new triple therapy regimen for eradicating Helicobacter pylori (abstract). Gut 1994;35 (Suppl 5):S16.Google Scholar
  167. 167.
    Jaup BH, Norrby A. Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. Am J Gastroenterol 1995;90:943–45.PubMedGoogle Scholar
  168. 168.
    Buckley M, Keating S, Xia H, Beattie S, Hamilton H, O'Morain C. Omeprazole plus one or two antibiotics to eradicate H. pylori (abstract). Gastroenterology 1995;108 (Suppl):A63.Google Scholar
  169. 169.
    Grasso GA, Battaglia G, Germana B, Lecis PE, Dal Bo N, Ferrana M, Salandin S, Benvenuti ME, Plebania M, Kusstatscher S, Vianello F, Di Mario F. Efficacy of low doses of clarithromycin for one week in eradicating H. pylori (abstract). Gut 1995;37 (Suppl 1):A47.Google Scholar
  170. 170.
    Jaup BH, Norrby A. Comparison of two low dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection (abstract). Gastroenterology 1995;108 (Suppl):A123.Google Scholar
  171. 171.
    Labenz J, Stolte M, Rühl GH, Becker T, Tillenburg B, Sollböhmer M, Börsch G. One-week low-dose triple therapy for the eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1995;7:9–11.PubMedGoogle Scholar
  172. 172.
    Labenz J, Peitz U, Tillenburg B, Becker T, Börsch G, Stolte M. Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori. Leber Magen Darm 1995;25:125–27.Google Scholar
  173. 173.
    Labenz J, Adamek RJ, Idström JP, Peitz U, Tillenburg B, Börsch G. Duodenal ulcer healing and Helicobacter pylori eradication by one-week low-dose triple therapy with omeprazole, clarithromycin and metronidazole (abstract). Gut 1995;37 (Suppl 1):A41.Google Scholar
  174. 174.
    Lind T, Veldhuyzen van Zanten SJO, Unge P, Spiller RC, Bayerdörffer E, O'Morain C, Wrangstadh M, Idström JP. The MACH 1 study: optimal one-week treatment for Helicobacter pylori defined? (abstract). Gut 1995;37 (Suppl 1):A4.Google Scholar
  175. 175.
    Deltenre M, Jonas C, Burette A, Klack R, De ReucK M, De Koster E. Bazzoli-like schemes are not optimal treatment for Helicobacter pylori eradication in Brussels, Belgium (abstract). Gastroenterology 1996;110 (Suppl):A93.Google Scholar
  176. 176.
    Misiewicz JJ, Harris AW, Bardhan KD, Levi S, Langworthy H. One week low-dose triple therapy for eradication of H. pylori: a large multicentre, randomised trial (abstract). Gut 1996;38 (Suppl 1):A1.PubMedGoogle Scholar
  177. 177.
    Sito E, Konturek PC, Bielanski W, Kwiecien N, Konturek SJ, Baniukiewicz A, Jedynak M, Gabryelewicz A, Hahn EG. Week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients. J Physiol Pharmacol 1996;47:221–28.PubMedGoogle Scholar
  178. 178.
    Goddard A, Logan R. One-week low-dose triple therapy: New standards for Helicobacter pylori treatment. Eur J Gastroenterol Hepatol 1995;7:1–3.PubMedGoogle Scholar
  179. 179.
    Schutze K, Hentschel E. Lansoprazole plus clarithromycin and amoxicillin in the short-term treatment of duodenal ulcer (abstract). VIIIth International Workshop on Gastroduodenal Pathology and Helicobacter pylori 1995;Edinburgh (Scotland).Google Scholar
  180. 180.
    Laine L, Estrada R, Trujillo M, Fukanaga K, Neil G. Randomized comparison of 7, 10 and 14 days of omeprazole, amoxicillin and clarithromycin for treatment of H. pylori (abstract). Gastroenterology 1996;110:A168.Google Scholar
  181. 181.
    Mones J, Ricart E, Sainz S. Helicobacter pylori eradication. Omeprazole, amoxicillin and clarithromycin: 1 week versus 2 weeks (abstract). Gastroenterology 1996;110:A201.Google Scholar
  182. 182.
    Peitz U, Tillenburg B, Becker T, Stolte M, Börsch G, Labenz J. Highly effective well tolerated one-week triple therapy with omeprazole, clarithromycin and amoxicillin for Helicobacter pylori infection (abstract). Gastroenterology 1996;110: A226.Google Scholar
  183. 183.
    Labenz J, Stolte M, Peitz U, Tillenburg B, Becker T, Börsch G. One-week triple therapy with omeprazole, amoxicillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1996;10:207–10.PubMedGoogle Scholar
  184. 184.
    Yousfi MM, El-Zimaity HMT, Cole RA, Genta RM, Graham DY. One week triple therapy with omeprazole, amoxicillin and clarithromycin for treatment of Helicobacter pylori infection (abstract). Gastroenterology 1996;110:A304.Google Scholar
  185. 185.
    Bell GD, Powell KU, Burridge SM, Bowden AF, Atoyebi W, Bolton GH, Jones PH, Brown C. Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 1995;9:41–46.Google Scholar
  186. 186.
    Kuwayama H. Zinc compound is a novel highly effective triple therapy for eradication of Helicobacter pylori (abstract). Gastroenterology 1995;108:A139.Google Scholar
  187. 187.
    Tucci A, Corinaldesi R, Stanghellini V, Paparo GF, Gasperoni S, Biasco G, Varoli O, Ricci-Maccarini M, Barbara L. One-day therapy for treatment of Helicobacter pylori infection. Dig dis Sci 1993;38:1670–73.PubMedGoogle Scholar
  188. 188.
    Dobrucali A, Tuncer M, Bal K, Uzunismail H, Yurdakul I, Altin M, Oktay E. One-day, high dose combined therapy of Helicobacter pylori infection. Gut 1995;37 (Suppl 2):A240.Google Scholar
  189. 189.
    Takats A, Racz I, Boga B, Gero G. Efficacy of a ‘one-daytriple-therapy’ with potentialisation of omeprazole for eradication of Helicobacter pylori (abstract). Am J Gastroenterol 1994;89:1399.Google Scholar
  190. 190.
    Tucci A, Poli L, Mazzoni C, Paparo GF, Caletti G, Bocus P, Ferrari A, De Giorgio R, Biasco G, Stanghellini V, Corinaldesi R. Week-end therapy for Helicobacter pylori eradication (abstract). Gastroenterology 1995;108 (Suppl):A246.Google Scholar
  191. 191.
    Kung NNS, Sung JY, NG, PW, Yuen WF, Chung E, Lim BH, Kwok S, Ma HC. Two-day versus one-week anti-Helicobacter pylori therapy for non-actively bleeding ulcers: a prospective randomised study (abstract). Gastroenterology 1996;110 (Suppl):A164.Google Scholar
  192. 192.
    De Boer W, Driessen W, Tytgat G. Only four days of quadruple therapy can effectively cure Helicobacter pylori infection. Aliment Pharmacol Ther 1995;9:633–38.PubMedGoogle Scholar
  193. 193.
    Wermeille J, Cunningham M, Armenian B, Zelger G, Hadengue A, Michel JP, Buri P. One-day therapy for Helicobacter pylori eradication. In press.Google Scholar
  194. 194.
    Peterson WL, Sontag SJ, Ciociola AA, Sykes DL, McSorley DJ, Webb DD. Ranitidine bismuth citrate plus clarithromycin is effective in the eradication of Helicobacter pylori and prevention of duodenal ulcer relapse (abstract). Gut 1995;37 (Suppl 1):A5.Google Scholar
  195. 195.
    Bardhan KD, Dallaire C, Eisold H, Duggan AE. The treatment of duodenal ulcer with GR122311X (ranitidine bismuth citrate) and clarithromycin (abstract). Gut 1995;37 (Suppl 1): A5.Google Scholar
  196. 196.
    Lanza F, Ciociola AA, Heath A, Sykes DL, McSorley DJ, Webb DD. Ranitidine bismuth citrate plus clarithromycin is effective in eradicating Helicobacter pylori, healing duodenal ulcers, and preventing ulcer relapse (abstract). Gastroenterology 1996;110:A172.Google Scholar
  197. 197.
    Pounder RE; Bailey R, Louw JA, Ohlin B, Dixon MF, Quirke P, Duggan AE. GR122311X (ranitidine bismuth citrate) with clarithromycin for eradication of Helicobacter pylori (abstract). Gut 1995;37 (Suppl 1):A42.Google Scholar
  198. 198.
    O'Morain C, Schulz TB, Tam C-Y, Dixon MF, Quirke P, Duggan AE. GR122311X (ranitidine bismuth citrate) with amoxycillin for eradication of Helicobacter pylori (abstract). Gut 1995;37 (Suppl 1):A42.Google Scholar
  199. 199.
    Butruk E, Ching CK, Schütze K, Duggan AE. The treatment of duodenal ulcer with GR122311X (ranitidine bismuth citrate) and amoxicillin (abstract). Gut 1995;37 (Suppl 1):A42.Google Scholar
  200. 200.
    Kimura K, Ido K, Saifuku K, Taniguchi Y, Kihira K, Satoh K, Takimoto T, Yoshida Y. A 1-h topical therapy for the treatment of Helicobacter pylori infection. Am J Gastroenterol 1995;90:60–3.PubMedGoogle Scholar
  201. 201.
    Corthésy-Theulaz I, Vaney AC, Haas R, Saraga E, Kraehenbühl JP, Blum AL, Michetti P. H. pylori urease B subunit as a therapeutic vaccine against H. Felis infection. Gastroenterology 1994;106:A668.Google Scholar
  202. 202.
    Batchelder M, Fox JG, Monath T, Yan L, Attardo L, Georgakopoulos K, Li X, Marini R, Shen Z, Pappo J, Lee C. Oral vaccination with recombinant urease reduces gastric Helicobacter pylori colonization in the cat. Gastroenterology 1996;110:A58.Google Scholar
  203. 203.
    Bell GD. Anti-Helicobacter pylori therapy: clearance, elimination, or eradication (letter)? Lancet 1991;337:310–11.CrossRefGoogle Scholar
  204. 204.
    Mégraud F. Advantage and disadvantage of current diagnostic tests for the detection of Helicobacter pylori. Scand J Gastroenterol 1996;31 (Suppl 215):57–62.Google Scholar
  205. 205.
    Borody T, Andrews P, Mancuso N, Jankiewicz E, Brandl S. Helicobacter pylori reinfection 4 years post-eradication (letter). Lancet 1992;339:1295.CrossRefGoogle Scholar
  206. 206.
    Forbes GM, Glaser ME, Cullen DJE, Warren JR, Christiansen KJ, Marshall BJ, Collins B. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet 1994;343:258–60.CrossRefPubMedGoogle Scholar
  207. 207.
    Penston JG. Review article: Helicobacter pylori eradication-understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994;8:369–89.PubMedGoogle Scholar
  208. 208.
    Deltenre M, De Koster E, Caucheteur B, Otero J, Jonas C. Comment éradiquer Helicobacter pylori? Revue critique des traitements disponibles. Gastroenterol Clin Biol 1996;20:S44–S52.PubMedGoogle Scholar
  209. 209.
    Lamouliatte H, Cayla R, Talbi P, Zerbib F, Mégraud F. La trithérapie IPP-amoxicilline-clarithromycine pour l'éradication de Helicobacter pylori: l'association optimale en 1996? Gastroentrol Clin Biol 1996;20:A10–A11.Google Scholar
  210. 210.
    Bell GD, Powell KU, Burridge SM, Bowden AN, Rameh B, Bolton G, Purser K. Harrison G, Brown C, Gant PW, Jones PH, Trowell JE. Helicobacter pylori eradication: efficacy and side effect profile of a combination of omeprazole, amoxycillin and metronidazole compared with four alternative regimens. Q J Med 1993:86;743–750.PubMedGoogle Scholar
  211. 211.
    Lamouliatte H, Cayla R, Zerbib F, Talbi P, Mégraud F. Triple therapy using proton pump inhibitor-amoxicillin and clarithromycin for Helicobacter pylori eradication (abstract). Gut 1995;37 (Suppl 1):A91.Google Scholar
  212. 212.
    Cayla R, Zerbib F, De Mascarel A, Mégraud F, Lamouliatte H. Dual therapy with high dose of omeprazole versus triple therapy using omeprazole in combination with two antibiotics for Helicobacter pylori eradication (abstract). Am J Gastroenterol 1994;89:1366.Google Scholar
  213. 213.
    Reilly TG, Poxon V, Walt RP. The eradication of Helicobacter pylori in practice: an audit of three years clinical experience with peptic ulcer patients (abstract). Gut 1995;37 (Suppl 1):A87.Google Scholar
  214. 214.
    Labenz J, Leverkus F, Börsch G. Omeprazole plus amoxicillin for cure of Helicobacter pylori infection: factors governing the treatment success (abstract). Am J Gastroenterol 1994;89:1376.Google Scholar
  215. 215.
    Unge P, Ekström P. Effects of combination therapy with omeprazole and an antibiotic on Helicobacter pylori and duodenal ulcer disease. Scand J Gastroenterol 1993;28 (Suppl 196):17–18.Google Scholar
  216. 216.
    Erdag S, Bojko JB, Burlage M, Schwarzhoff R, Barden B, Lembcke B, Fölsch UR, Schmidt WE. Optimal compliance eliminates differences in eradication rates between 2-week dual and 1-week triple therapy for Helicobacter pylori gastritis (abstract). Gastroenterology 1996;110:A103.Google Scholar
  217. 217.
    De Bartolo M, Reltmayer R, Olson C, Edmonds A. Effect of smoking on Helicobacter pylori eradication and duodenal ulcer recurrence in patients receiving dual therapy with clarithromycin in combination with omeprazole (abstract). Gastroenterology 1995;108:A79.Google Scholar
  218. 218.
    Moayyedi P, Axon ATR. Patient factors that predict failure of omeprazole, clarithromycin and tinidazole to eradicate Helicobacter pylori (abstract). Gut 1995;37 (Suppl 1):A46.Google Scholar
  219. 219.
    Axon ATR, Moayyedi P. Eradication of Helicobacter pylori: omeprazole in combination with antibiotics. Scand J Gastroenterol 1996;31 (Suppl 215):82–9.Google Scholar
  220. 220.
    Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995;333:984–91.CrossRefPubMedGoogle Scholar
  221. 221.
    Holtmann G, Layer P, Goebell H. Proton-pump inhibitors or H2-receptor antagonists for Helicobacter pylori eradication-a meta-analysis (letter). Lancet 1996;347:763.CrossRefPubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • Joël Wermeille
    • 1
  • Georges Zelger
    • 2
  • Michael Cunningham
    • 3
  1. 1.Hôpital de GériatrieHôpitaux Universitaires de GenèveThônex/GenèveSwitzerland
  2. 2.Pharmacy, Hôpital de GériatrieHôpitaux Universitaires de GenèveSwitzerland
  3. 3.Gastroenterology DivisionHôpitaux Universitaires de GenèveSwitzerland

Personalised recommendations